FIGURE

Figure 5

ID

ZDB-FIG-191230-913

Publication

Cheng et al., 2019 - Ciglitazone-a human PPARγ agonist-disrupts dorsoventral patterning in zebrafish

Other Figures

All Figure Page

Back to All Figure Page

Figure 5

DMP reverses the ventralizing effects of ciglitazone.

Mean (+standard deviation) percent of normal, ventralized, dorsalized, delayed, or dead embryos following exposure to vehicle (0.2% DMSO), 0.078 µM DMP, 12.5 µM ciglitazone (Cig), or 0.078 µM DMP + 12.5 µM Cig (N = 60 embryos per treatment) (A). Asterisk (*) denotes a significant difference (p < 0.05) in the percent of normal embryos relative to vehicle (0.2% DMSO) controls. Representative images of embryos following exposure to vehicle (0.2% DMSO), 0.078 µM DMP, 12.5 µM ciglitazone, or 0.078 µM DMP + 12.5 µM Cig (B–E). Immunostaining with anti-phosphoSMAD-1/5/9 within 8-hpf embryos following exposure to vehicle (0.2% DMSO), 0.078 µM DMP, 12.5 µM Cig, or 0.078 µM DMP + 12.5 µM Cig; embryos exposed to 0.625 µM DMP were included as a positive control for disruption of BMP signaling gradients. Arrowheads point to elevated pSMAD 1/5/9 staining on the ventral side of the embryo (F–J).

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Fish:	WT
Conditions:	chemical treatment by environment: ciglitazone chemical treatment by environment: ciglitazone chemical treatment by environment: dorsomorphin
Observed In:	embryo development ending in birth or egg hatching whole organism
Stage:	Prim-5

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Peer J.